Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Sanofi, Hanmi seal diabetes licence deal for up to $4.2 bln (updated)

* Hanmi gets 400 mln euros upfront, up to 3.5 bln milestones 
    * Sanofi wins exclusive licence to long-acting GLP-1 drugs 
    * Deal seen as negative for existing Sanofi partner Zealand 
 
 (Adds analyst's comment, updates share price reaction) 
    By Matthias Blamont 
    PARIS, Nov 5 (Reuters) - Sanofi  SASY.PA  has signed a 
licence deal with Hanmi Pharmaceutical  128940.KS  to develop 
experimental, long-acting diabetes treatments, the French 
drugmaker said on Thursday, in a move to revive its diabetes 
division. 
    South Korea-based Hanmi will receive an upfront payment of 
400 million euros ($434 million) and is eligible for up to 3.5 
billion euros in development, registration and sales milestones, 
as well as double-digit royalties on net sales. 
    In return Sanofi will get an exclusive worldwide licence to 
develop and commercialise Hanmi's so-called GLP-1 diabetes 
treatments. Hanmi will retain an exclusive option to 
co-commercialise the products in Korea and China.  urn:newsml:reuters.com:*:nHUG7mbBM5 
    The deal marks a sizeable bet by Sanofi on a new technology 
at a time when its all-important diabetes business is 
struggling. 
    Nearly 400 million people worldwide have diabetes, with type 
2 accounting for more than 90 percent of cases. Without proper 
treatment or lifestyle changes those numbers are expected to 
grow substantially. 
    But Sanofi, which will unveil a five-year strategic plan on 
Friday, surprised investors last week when it said revenues at 
the division would keep falling until 2018, due to growing 
competition, especially in the United States.  urn:newsml:reuters.com:*:nL8N12T0VP 
    Although he did not refer specifically to diabetes, Chief 
Executive Olivier Brandicourt had told reporters on a results 
call that he was considering acquisitions and licensing deals. 
    The tie-up with Hanmi means Sanofi is investing heavily in 
the long-acting area where competitors like Denmark's Novo 
Nordisk  NOVOb.CO  and U.S.-based Eli Lilly  LLY.N  are also 
active. 
    Nordea analyst Michael Novod said the move was "very bad 
news" for Denmark's Zealand Pharma  ZELA.CO , which has an 
existing deal with Sanofi for a short-acting GLP-1 drug. 
    Zealand's shares fell 5 percent while Sanofi rose 1.8 
percent, slightly outperforming a 1.4 percent advance in the 
Stoxx Europe 600 healthcare sector index  0#.SXDP . 
    The agreement also illustrates the growing power of South 
Korea as a force in pharmaceutical research. 
    According to a study by Research and Markets published in 
May, the country is seen as one of the leaders in research and 
development in the Asia Pacific region thanks to the strong 
involvement of both the public and private sectors.  
($1 = 0.9225 euros) 
 
 (Additional reporting by James Regan; Editing by Ben Hirschler 
and Greg Mahlich) 
 ((james.regan@thomsonreuters.com;)(+33 1 49 49 53 84; Reuters 
Messaging:  james.regan.thomsonreuters.com@reuters.net)) 
 
Keywords: SANOFI HANMI/DIABETES

Recent news on Hanmi Pharm

See all news